Results 141 to 150 of about 32,102 (275)

Acute Systemic Complications Following High‐Dose Semaglutide Reinitiation in an Elderly Patient

Clinical Case Reports, Volume 14, Issue 5, May 2026.
ABSTRACT Severe gastrointestinal intolerance with systemic complications can occur within hours of reinitiating high‐dose semaglutide after a prolonged treatment interruption, even in patients who previously tolerated the medication. Elderly patients with comorbidities may be particularly vulnerable.
Jay Mehta, Brent Tai, Johnathan Frunzi
wiley   +1 more source

Wernicke’s Encephalopathy Secondary to Hyperemesis Gravidarum in Pregnancy: A Case Report

Clinical Case Reports, Volume 14, Issue 5, May 2026.
ABSTRACT Wernicke's Encephalopathy, although classically associated with chronic alcoholism, can also occur during pregnancy as a complication of hyperemesis gravidarum and is often underdiagnosed. We report a case of a 34‐year‐old pregnant woman at 16 weeks of gestation who presented with prolonged vomiting, altered mental status, nystagmus, and gait ...
Abhishek Mahato, Sameer Parajuli, Bandana Ghimire, Bishal Basnet, Bishal Sigdel, Bishal Kumar Yadav, Sagar Kumar Jha   +6 more
wiley   +1 more source

The Efficacy and Toxicity of CNS Prophylaxis in Diffuse Large B‐Cell Lymphoma (CLSG‐CNS‐01): A Randomized, Multicenter, Prospective Phase 3 Trial

Hematological Oncology, Volume 44, Issue 3, May 2026.
ABSTRACT The randomized, multicenter, prospective Phase 3 trial (NCT02777736) evaluated central nervous system (CNS) prophylaxis using either intravenous (i.v.) or intrathecal (i.t.) methotrexate (MTX) in diffuse large B‐cell lymphoma (DLBCL). Treatment consisted of six cycles of R‐CHOP + 2xR or DA‐EPOCH‐R + 2xR. Patients with intermediate or high‐risk
H. Mocikova, L. Gaherova, T. Jancarkova, A. Suri, A. Janikova, K. Steinerova, D. Belada, R. Pytlik, J. Duras, M. Trnkova, P. Blahovcova, T. Kozak, M. Trneny   +12 more
wiley   +1 more source

Nature and Incidence of Post‐Anesthesia Complications in the Recovery Care Units Among Postoperative Patients in Palestinian Hospitals: A Cross‐Sectional Study

Health Science Reports, Volume 9, Issue 5, May 2026.
ABSTRACT Background and Aims The early postoperative period is defined as a moment of high vulnerability for patients. This period places patients at increased risk for increased physiological problems and complication rates. These complications pose a noteworthy challenge to patient safety and can lead to prolonged hospital stays and increased burden ...
Ashraf Jehad Abuejheisheh, Rabia Hani Haddad, Fatma Kamal Ali, Nedal F. Abu Jasser, Dania Jawabrah, Shatha Halaiqa, Maysarah Mosleh, Nizar Hrinat, Saif Tawayha, Dina Hamad, Kefah Zaben, Farid Ghrayeb   +11 more
wiley   +1 more source

Tratamiento de la emesis inducida por citotóxicos

Psicooncologia, 2004
Nausea and vomiting are important side effects of most chemotherapy anticancer drugs, since nearly two thirds of the patients under chemotherapy have this toxicity in absence of antiemetic treatment.
Miguel Martín, Sara López
doaj  

Efficacy and safety of fruquintinib combined with albumin‐bound paclitaxel as second‐line therapy for advanced gastric cancer following failure of PD‐1 inhibitor‐containing treatment (TACTIC GC‐01): A phase II single‐arm study

International Journal of Cancer, Volume 158, Issue 9, Page 2219-2228, 1 May 2026.
What's new? Anti‐angiogenic drugs have shown promising efficacy as a second‐line treatment for advanced gastric cancer. However, it remains unclear how alterations in the tumor microenvironment following first‐line immunotherapy may impact tumor angiogenesis and influence subsequent therapeutic outcomes. This single‐arm study prospectively explored the
Xiaoting Ma, Kai Ou, Xiu Liu, Biyang Cao, Wenwei Yang, Jingyu Lu, Letian Zhang, Qi Wang, Lizhen Gao, Zhichao Jiang, Yongkun Sun, Lin Yang   +11 more
wiley   +1 more source

Association of a Fixed 1 mg Dose of Granisetron for Preventing Postoperative Nausea and Vomiting (PONV) in Patients Undergoing Laparoscopic Colorectal Surgery With Multiple PONV Risk Factors: A Retrospective Observational Study. [PDF]

Cureus
Morimoto T, Hara K, Nishigaki A, Tashiro K, Nakao A, Nagaoka K, Yamaguchi M, Hara T.   +7 more
europepmc   +1 more source

A Phase 1 Oral Mass Balance and Combined Intravenous [14C] Microtracer Study to Characterize the Absorption, Metabolism, Excretion, and Pharmacokinetics of Antitumor Drug E7386 in Humans

The Journal of Clinical Pharmacology, Volume 66, Issue 5, May 2026.
Abstract E7386, an orally active protein‐protein interaction inhibitor, is reported to impair the interaction between transcriptional co‐activator CREB‐binding protein and β‐catenin. A competent study design exploring the concomitant dosing routes, sensitive intravenous (IV; [14C]) microtracer technology, and oral [14C] radiolabeled dosing was ...
Shriram M. Pathak, Nozomi Hayata, Takashi Ueno, Jagadeesh Aluri, Jincao Wu, Ashley S. Brooks, Catherine M. Laing, Lea Dutta, Sanae Yasuda   +8 more
wiley   +1 more source

Megestrol acetate versus dexamethasone to prevent nausea and vomiting in patients with gastric or gastro-oesophageal junction cancer treated with oxaliplatin-based chemotherapy: study protocol of a multicentre, randomised, non-inferiority trial. [PDF]

BMJ Open
Luo H, Hu Q, Zeng L, Huang Q, Luo Y, Li T, Chen P, Yi C, Gou H.   +8 more
europepmc   +1 more source

Should PNPO Deficiency Be Treated In Utero? Clinical Findings From Prenatal Pyridoxine Therapy

JIMD Reports, Volume 67, Issue 3, May 2026.
ABSTRACT Pyridox(am)ine‐5′‐phosphate oxidase (PNPO) deficiency is characterized by early‐onset epileptic encephalopathy refractory to standard antiseizure medications. It is caused by variants in the PNPO gene, resulting in deficient PNPO enzyme activity, which normally converts pyridoxine‐5′‐phosphate and pyridoxamine‐5′‐phosphate (two vitamers of ...
Chloé de Puyraimond, Samia Pichard, Muriel Girard, Julian Delanne, Laurence Faivre, Apolline Imbard, Amandine Baurand, Jean‐François Benoist, Philippa B. Mills, Peter T. Clayton, Manuel Schiff   +10 more
wiley   +1 more source